Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Allegion's stock has climbed over 30% in the past year, raising questions about its current valuation. A deep dive into the numbers reveals a mixed picture, with key metrics pointing in opposite directions.
Amid a quarter dominated by mega-cap tech and AI fervor, Pzena Investment Management's value-focused fund highlighted discount retailer Dollar General as a key performer, driven by strong earnings that propelled its stock.
CME Group has increased margin requirements for precious metals futures and options following extreme price swings, as daily trading volumes hit record highs. The exchange is also introducing new silver products and enforcing compliance measures, highlighting its dual role as a market facilitator and risk manager during turbulent times.
Despite modest revenue growth and lack of profitability, Cognyte Software (NASDAQ: CGNT) has delivered a remarkable 133% return to shareholders over the past three years, highlighting a stark divergence between financial fundamentals and market optimism.
Footwear giant Deckers Brands announced a 7.1% rise in Q3 FY26 net sales to $1.95 billion, driven by explosive growth from its HOKA running brand and solid gains from UGG, despite a challenging retail environment.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
The asset manager declares a $0.03 per share payout, with its dividend yield sitting below industry average as a rising stock price and robust earnings growth paint a complex picture for income-focused investors.
SEI Investments (SEIC) has delivered impressive returns for shareholders over the past five years, but a closer look at its current valuation suggests the stock may have run ahead of its fundamentals. With shares trading near $88, analysis indicates potential overvaluation, prompting investors to weigh future growth against present price.
The industrial sector has outperformed the broader market, buoyed by regulatory shifts. However, not all companies are equally positioned. We analyze one stock with a durable edge and two facing potential headwinds.
The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Mitsubishi UFJ Financial Group's shares have surged nearly 50% in the past year, capping a remarkable five-year run. As the stock trades near ¥2,751, investors are divided: does the valuation still offer a margin of safety, or has the rally run its course? We delve into the metrics and market sentiment.
Tyson Foods shares have rallied over 12% this year, pushing its price toward $65. But a deep dive into valuation metrics reveals a complex picture: while a cash flow model suggests significant upside, its lofty P/E ratio tells a cautionary tale. Investors are left weighing growth expectations against current premiums.
Despite a strong 33% gain over the past year, Lear Corporation's recent stock performance shows signs of cooling. A deep dive into its discounted cash flow and earnings multiples suggests the market may still be undervaluing this automotive seating and electronics supplier.
The Kospi index plunged over 5% in its sharpest drop since April, halting program trading and dragging down chip giants Samsung and SK Hynix. The selloff, fueled by global risk-off sentiment and doubts over AI spending, tests the resilience of one of the world's hottest equity markets.
RATIONAL AG's stock has seen a notable 12% climb on the XTRA exchange in recent months, reigniting investor debate. Our analysis suggests the shares may now be overvalued, trading above intrinsic value. We examine the outlook, growth potential, and whether investors should wait for a better entry point.
A surge of competitively priced Chinese electric vehicles and consumer goods is rapidly transforming Latin American markets, forcing governments from Mexico to Brazil to enact new tariffs and trade defenses to shield domestic industries from the influx.
Shares of security products giant Allegion have gained significant momentum, delivering a 26% total return over the past year. With the stock now trading near $165, we examine whether its current valuation still offers an attractive entry point or if future growth is already priced in.
Shares of Tyson Foods (TSN) have climbed over 12% in the past month, reigniting discussions on Wall Street about the meatpacking giant's valuation. While some analysts see room for further growth, others caution that recent gains may have outpaced fundamentals.
